The H2S-releasing naproxen derivative, ATB-346, inhibits alveolar bone loss and inflammation in rats with ligature-induced periodontitis by Herrera, Bruno Schneider et al.
  Universidade de São Paulo
 
2015
 
The H2S-releasing naproxen derivative, ATB-
346, inhibits alveolar bone loss and
inflammation in rats with ligature-induced
periodontitis
 
 
Medical Gas Research. 2015 Feb 27;5(1):4
http://dx.doi.org/10.1186/s13618-015-0025-3
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Farmacologia - ICB/BMF Artigos e Materiais de Revistas Científicas - ICB/BMF
RESEARCH Open Access
The H2S-releasing naproxen derivative, ATB-346,
inhibits alveolar bone loss and inflammation in
rats with ligature-induced periodontitis
Bruno Schneider Herrera1,2, Leila Santana Coimbra2, Agatha Ribeiro da Silva1, Simone Aparecida Teixeira1,
Soraia Katia Pereira Costa1, John Lawrence Wallace3, Luis Carlos Spolidorio2 and Marcelo Nicolas Muscara1*
Abstract
Background: In experimental periodontitis, non-steroidal antiinflammatory drugs (NSAIDs) effectively inhibit the
resultant alveolar bone loss. However, their deleterious gastric effects, observed in both animals and humans,
dramatically limit their long-term use. It has been proven that the addition of a hydrogen sulfide (H2S)-releasing
moiety to classical NSAID structures results in antiinflammatory compounds with improved gastric safeness. In this
way, we decided to compare the effects of naproxen with its H2S-releasing derivative ATB-346 on ligature-induced
periodontitis in rats.
Methods: Male Holtzman rats had a cotton ligature placed subgingivally around the lower right first molar during
7 days. During this period, groups of animals were daily treated with Na2S (a spontaneous H2S donor) or equimolar
oral doses of naproxen (10 mg/kg) or ATB-346 (16 mg/kg). The mandibles were finally collected for histological
analysis, radiographical measurements of alveolar bone loss and micro-computed tomography (μCT) analysis.
Interleukin (IL)-1β, IL-6 and IL-10 were quantified in gingiva samples, and the stomachs were also collected for
scoring of tissue damage and measurement of myeloperoxidase (MPO, a marker of granulocyte infiltration).
Results: Ligature-induced bone loss was significantly inhibited by all the treatments, although only ATB-346
treatment resulted in significant inhibition of bone defect and other histological characteristics (such as flatness of
the gingival epithelium, chronic inflammatory cell infiltration and loss of connective tissue in the gingival papillae).
Both naproxen and ATB-346 inhibited the increase of gingival IL-1β and IL-6 secondary to periodontitis, but IL-10
was unaffected. Significant damage and increased MPO contents were only found in the stomachs of the
naproxen-treated animals.
Conclusion: The H2S-releasing moiety in the ATB-346 compound not only does not impair the effects of the parent
naproxen on periodontitis, but also improves bone quality and prevents the gastric mucosa damage due to
prostaglandin inhibition, thus configuring a potentially new adjuvant therapy for periodontal diseases.
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Introduction
Periodontitis is a chronic inflammatory disease and a
major public health concern considering that that it is
among the most prevalent human diseases [1]. It is trig-
gered by bacterial biofilms and, with other periodontal
diseases, comprise a unique and complex group of in-
flammatory conditions that result in the destruction of
the supporting structures of the dentition [2]. While the
etiology of periodontitis is bacterial, it is becoming clear
that the pathogenesis of disease is mediated by the host
response [3].
Some studies show that periodontitis is associated with
other several inflammatory conditions, such as arthritis,
type-II diabetes, preeclampsia, preterm low birth weight,
and cardiovascular diseases [4-9]. Since the pathogenesis
of periodontitis shares similar aspects with many other
inflammatory diseases, animal models of the disease are
recognized as valid tools for the study of effector cell
mediated inflammation [10].
In inflamed periodontal tissues, cylooxygenase-2 (COX-2)
expression is significantly up-regulated [11] and COX-2-
derived prostaglandin E2 (PGE2), produced by activated
macrophages and fibroblasts, is present in the crevicular
fluid of patients with periodontitis and considered as one
of the major inflammatory mediators of alveolar bone
destruction [12,13]. In fact, alveolar bone loss secondary
to ligature-induced periodontitis in rats is significantly
reduced during treatment with either selective COX-2 in-
hibitors [14,15] or traditional non-selective NSAIDs
[16-18]. In humans, PGE2 is associated with disease ag-
gressiveness and can be used as a reliable indicator of
current clinical periodontal destruction [19].
In this way, COX inhibition by NSAIDs would be an
attractive clinical pharmacological approach aimed to
reduce both PGE2 production at the site of inflammation
and tissue destruction [14,15]. However, the chronic use
of NSAIDs is limited by the well-known, and clinically
relevant, renal and cardiovascular occurrences, in addition
to gastrointestinal ulceration and bleeding [20,21].
In this way, new classes of NSAIDs capable of releas-
ing nitric oxide (NO) [22] or H2S [23-27] in vivo have
been developed, with basis on the ability of these media-
tors to effectively antagonize many of the deleterious
side-effects of traditional NSAIDs. For example, several
studies show that the new H2S-releasing NSAIDs, such
as those derived from mesalamine [23,24], indometacin
[27], diclofenac [26] or naproxen [25,28-30], present
significant advantages over the parent NSAIDs, with no
impact on cardiovascular system, decreased gastric
effects, and even accelerated healing activity of pre-
existing gastric ulcers [25].
Using a rat model of knee joint synovitis, we have
recently shown that, despite the similar effects of both
naproxen and its H2S-releasing derivative ATB-346 on
inhibiting joint pain, edema and inflammatory cell re-
cruitment to the knee-joint cavity, the H2S-releasing
NSAID exerted no significant gastric damage, thus mak-
ing of ATB-346 an interesting therapeutic alternative to
traditional naproxen [30].
Regarding the relationship between H2S and periodon-
titis, published studies show discrepant results depending
on the H2S donor employed, the administration route and
doses [31-33].
Based on the considerations above, we thus decided to
study the effects of the administration of Na2S (an H2S
donor), naproxen and its H2S-releasing derivative ATB-
346 in rats with ligature-induced periodontitis.
Material and methods
Animals
All the experimental protocols were approved by the
local Ethics Committee for Animal Experimentation and
performed in accordance with the guidelines of the
Brazilian College for Animal Experimentation (COBEA).
Male adult Holtzman rats (Rattus norvergicus albinus)
weighing 250–300 g, were used in the experiments.
During the length of the experimental protocol, the rats
were kept in a quiet room with controlled temperature
(22 ± 1°C), humidity (65-75%) and a 12-h light–dark
cycle, and they were fed standard rat chow and received
tap water ad libitum.
Chemicals
All the drugs and reagents were purchased from Sigma-
Aldrich (Brazil), unless otherwise stated.
Induction of periodontitis, treatments and sample collection
The rats were anesthetized with ketamine (80 mg/kg, i.
p.; Francotar, Virbac do Brasil Ind. e Com. Ltda, Brazil)
and xylazine (16 mg/kg, i.p.; Kensol, Konig S.A., Brazil)
and a 3–0 cotton ligature was placed subgingivally
around the lower right first molar, as previously de-
scribed [34]. Sham-operated animals had the ligature im-
mediately removed after the procedure.
Following ligature placement, groups of animals
started to receive daily oral doses of Na2S (dissolved in
the drinking water at 45 mg/L, equivalent to a daily dose
of approximately 10–12 mg/kg/day), equimolar doses of
naproxen (10 mg/kg) or ATB-346 (16 mg/kg; Antibe
Therapeutics Inc., Toronto, ON, Canada), or vehicle
(1 ml/kg of 0.5% CMC). Treatments continued during
the next 7 days, when the animals were euthanised.
Samples of gingiva surrounding the ligatured tooth were
collected for measurement of cytokine contents, and the
corpus region of the stomachs were also excised for assess-
ment of macroscopical tissue damage and myeloperoxidase
activity content (see below). The mandibles were removed
for bone loss and histological analysis as shown below.
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Bone loss analysis
Digital X-ray images were also obtained for alveolar
bone loss estimation by measurement of the distance be-
tween the cement-enamel junction (CEJ) and the alveo-
lar bone crest at the mesial face of the ligatured tooth.
Histological analysis
The madibles were kept in 10% formaldehyde solution
during 48 h, followed by decalcification of the right
hemi-mandibles in 4.13% EDTA (pH 7.2) at 4°C for ap-
proximately 3 months. Serial paraffin sections of 5 μm
thickness were made on the mesial-distal aspects of the
whole first lower right molars and stained with
hematoxylin and eosin (H&E). Morphological studies were
made on the buccal and lingual gingiva and alveolar bone.
Micro-computed tomography (μCT) analysis
For quantitative and qualitative three-dimensional (3D)
analysis of the alveolar bone defect, right hemi-
mandibles of 5 rats per group were scanned dorso-
ventrally using a microfocus X-ray CT system (Skyscan,
Aartselaar, Belgium, 2003). The sagittal plane of the
specimens was set parallel to the X-ray beam axis. The
specimens were scanned at a resolution of 8.8 μm in all
three spatial dimensions. The scans were gaussian-
filtered and segmented using a multilevel global thresh-
olding procedure for the segmentation of enamel,
dentin, and bone [35]. CTan/CTvol software (Skyscan,
Aartselaar, Belgium, 2003) was used for imaging and
analysis. The volume of interest (VOI) was drawn with a
slice-based method starting from the first slice contain-
ing the cement-enamel junction of the first molar and
moving dorsally for 168 slices in the area 3 mm above
the cement enamel junction. On the original 3D image,
the microstructural variables, area and volume of bone
defect, were calculated directly from the binarized VOI.
Analysis of gingival cytokine contents
Interleukin (IL)-1β, IL-6 and IL-10 were measured in the
collected gingiva samples by ELISA using commercial
kits (R&D Systems Inc., Minneapolis, MN, USA) follow-
ing the manufacturer instructions. Total protein con-
tents were quantified according to the method described
by Bradford et al. [36].
Gastric damage assessment
At the end of the 7-day treatment period, the rats were
euthanized and the stomachs were excised. The severity
of damage was blindly scored as described in detail pre-
viously [37]. The length of each hemorrhagic erosion (in
mm) was measured from the digitalized pictures using
the software ImageJ (NIH, USA), and a gastric damage
score was calculated by summing the lengths of all ero-
sions in each stomach.
In addition, the activity of myeloperoxidase (MPO), a
hemoprotein located in azurophilic granules of neutro-
phils, was used as a biochemical marker of neutrophil
infiltration into the collected stomach samples, and
was spectrophotometrically measured as previously de-
scribed [38].
Statistical analysis
All data are expressed as mean ± SEM. Differences among
the group means were analyzed by one-way ANOVA
followed by Tukey’s test for multiple comparisons. Values
of P < 0,05 were considered as statistically significant.
Results
Ligature induced bone loss
As shown in Figure 1 (panel A), after 7-day ligature,
significant alveolar bone resorption was observed in
the vehicle-treated animals in comparison with the
Sham group, as radiographically assessed by meas-
urement of the distances between the CEJ and the
alveolar bone crest (0.80 ± 0.06 vs. 0.14 ± 0.04 mm, P <
0.001). Bone loss was significantly inhibited by all of
the treatments (naproxen: 0.62 ± 0.05 mm, P < 0.05;
ATB-346: 0.46 ± 0.04 mm, P < 0.01; Na2S: 0.4 ± 0.1 mm,
P < 0.001).
Histological analysis
Figure 1 also shows that normal morphology was ob-
served in the Sham rat gingiva obtained from both the
vestibular and lingual faces of the lower first molar. The
oral, sulcular and junctional epithelium presented clas-
sical structures, and the connective tissue was dense,
formed by thick collagen fibers, interspersed with deli-
cate vessels and fibroblasts. Few inflammatory cells were
found in the junctional epithelium region (panel B1).
The presence of a cotton ligature in a submarginal
position around the lower first molar induced the clas-
sical microscopic characteristics of periodontitis, such as
flatness of gingival epithelium, intense infiltration of
chronic inflammatory cells, presence of giant cells, loss
of connective tissue in the gingival papillae and evident
alveolar bone resorption activity (panels B2 and C1).
Na2S treated rats presented with evident decrease of the
extension of chronic inflammation and partially con-
served the connective tissue papillae, which is associated
with milder bone resorption activity (panel B3). Na-
proxen treatment did not result in microscopic changes
of the aspect of ligature-induced host response when
compared with the vehicle-treated rats (panels B2 and
C2). However, the administration of ATB-346 resulted in
marked inhibition of the ligature-induced host response
in the gingival tissues, characterized by the evident de-
crease of the extension of chronic inflammatory cells,
giant cells and partially conserved connective tissue
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papillae, as indicated by the preservation of collagen fi-
bers and gingival epithelium (panel C4).
Bone defect area and volume values analyzed by μCT
In addition to the inflammation and bone loss caused by
the presence of the ligature around the first molar dur-
ing 7 days, significant defects were induced in bone area
and volume (area: 0.50 ± 0.13 vs. 0 ± 0 mm2, P < 0.001;
volume: 3.24 ± 0.24 vs. 0 ± 0 mm3, P < 0.001; Figure 2,
panels A and B, respectively). Treatment of the animals
with naproxen potentiated these ligature-induced defects
(area: 0.95 ± 0.03 mm2, P < 0.001; volume: 4.58 ± 0.07 mm3,
P < 0.001). However, these bone defect parameters were
significantly reduced in the ATB-346-treated rats (area
0.21 ± 0.05 mm2, P < 0.001; volume: 2.17 ± 0.2907 mm3,
P < 0.01).
Gingival inflammatory cytokines
As shown in Figure 3, the presence of ligature induced
significant increases in the gingival contents of IL-1β
and IL-6, as well as decreased IL-10, in comparison with
the Sham animals (IL-1β: 134.8 ± 29.1 vs. 15.3 ± 1.5 pg/mg
of protein; IL-6: 13.7 ± 1.2 vs. 5.6 ± 0.5 pg/mg of protein;
IL-10: 0.6 ± 0.2 vs. 2.9 ± 0.4 pg/mg of protein; P < 0.001 for
all the three cytokines). Treatment with either naproxen,
ATB-346 or Na2S resulted in significant decrease of
gingival IL-1β contents (61.4 ± 7.8, 33.3 ± 6.0 and
31.2 ± 2.6 pg/mg of protein, respectively; panel A),
but only naproxen and ATB-346 resulted in decreased
IL-6 (6.8 ± 0.8 and 6.1 ± 1.0, respectively; panel B). Re-
garding IL-10 contents, none of the treatments af-
fected the ligature-induced decrease; panel C).
Gastric effects
As shown in Figure 4, the presence of ligature had no gas-
tric effect, as assessed by either MPO activity (panel A) or
macroscopical damage assessment (panels B and C). Only
the naproxen-treated animals showed significantly in-
creased gastric MPO activity (16.1 ± 3.8 U/mg tissue; P <
0.001 vs. all the remaining groups), which was paralleled
by the gastric damage score (17 ± 3 vs. 0 for all the
remaining groups; P < 0.001).
Discussion
During the development of periodontal disease, bacteria
and their products form a biofilm covering the tooth
surface in the subgingival area, which can have direct
deleterious effects on periodontal tissues [2]. In susceptible
Figure 1 Ligature-induced alveolar bone loss and the inflammatory parameters is reduced in rats treated with naproxen or its
H2S-releasing derivative ATB-346. Panel A: Distance from the cemento-enamel junction (CEJ) to the alveolar bone crest analyzed by digital
X-ray images (n = 8). **P < 0.01 and ***P < 0.001 vs. Sham; #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. Vehicle. Histological aspect of gingival tissues.
Panel B (4 × magnification): 1. Control, 2. Vehicle, 3. Na2S; panel C (20 × magnification): 4. Control, 6. Vehicle, 8. Naproxen, 10. ATB-346 (the
respective inserts 5, 7, 9 and 11 are at a 10 × magnification). Δ: Giant cells;→: markedly reduced cellular infiltrate, preserved collagen fibers and
gingival epithelium in comparison with the other groups.
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individuals, the host-mediated response to the pathogenic
flora is subsequently responsible for the destruction of
periodontal connective tissues, including alveolar bone
[39,40].
The use of NSAIDs is one of the most widely used
pharmacological tools to intervene and inhibit an in-
flammatory response, by antagonizing pro-inflammatory
pathways and/or signaling, mainly dependent on COX-
derived eicosanoids [41]. Although previous reports
show that the NSAID treatment of rats with experimen-
tally induced periodontitis leads to inhibition of peri-
odontium inflammation and bone loss [14,15], NSAID
therapy is not applicable for treatment of clinical peri-
odontitis [42]. Unfortunately, and despite the magnitude
of the clinical improvement is measurable, the need for
prolonged therapy discourages the long-term use of
NSAIDs in face of their severe cardiovascular, renal and
gastric side effects [20,21].
One proposed strategy to avoid systemic complications
and, at the same time, achieving high concentrations of
the drug at the diseased site, has been the development
of topical NSAID formulations (such as gels, toothpastes
or mouth rinses) to be locally applied on a daily basis.
However, evidence shows that just transient effects
occur after the NSAID is withdrawn; in addition, no
long-term or multicenter prospective clinical trials have
been perfomed to date examining whether the thera-
peutic effects of topical NSAIDs can be retained on a
long-term basis [16].
In this study, we show that the development of experi-
mental periodontitis in rats was significantly inhibited by
treatment of the animals with a new H2S-releasing na-
proxen derivative - ATB-346, as clearly evidenced by the
diminished alveolar bone loss, defect volume and area.
In addition, we also show that the intense infiltration of
chronic inflammatory cells and loss of connective tissue
in the gingival papilla secondary to the presence of peri-
odontitis was inhibited not only by treatment with ATB-
346, but also with the inorganic H2S donor Na2S, thus
reflecting the importance that exogenous H2S has by it-
self in the control and progression of periodontal disease
in rats. Furthermore, the stomachs from animals treated
with ATB-346 did not show the increased neutrophil
contents (i.e., MPO activity) or tissue damage observed
in the stomachs from the naproxen treated animals, thus
demonstrating clear beneficial effects of ATB-346 over
the parent drug. Indeed, it is based on these gastric
protective properties without loss of its antiinflamma-
tory activity that has led ATB-346 to undergo a phase I
clinical trial for safety and pharmacokinetic evaluations
in healthy human subjects (Antibe Press Release, Oct.
6, 2014).
Figure 2 Micro-computed tomography (μCT) shows that ATB-346 inhibited the increase of the bone area and volume secondary to
ligature-induced periodontitis. Bone analysis by μCT in terms of both area (panel A) and volume (panel B) of bone defect. *P < 0.05 and ***P
< 0.001 vs. Sham; ##P < 0.01 and ###P < 0.001 vs. Vehicle; ϕϕP < 0.01 and ϕϕϕP < 0.001 vs. Naproxen Panel C: Representative three-dimensional
reconstructions of μCT analysis performed on the left hemimandible of the animals subjected to periodontitis. Panel D: μCT images on the
sagittal plane of the left hemimandible of the animals depicting the alveolar bone in the interradicular area (n = 6 for each experimental group).
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H2S is produced in virtually every organ system in the
body [43,44], and some studies show that H2S contrib-
utes to the maintenance of tissue and organ integrity
during inflammation by acting as resolution mediator
[25,45,46]. Resolution of inflammation is an active,
agonist-mediated and well-orchestrated process that
drives the return to tissue homeostasis [47], and emer-
ging evidence suggests that non-resolving inflammation
is a critical underlying component of many prevalent
chronic diseases, including periodontal disease [9]. In
fact, El-Sharkawy et al. [48], showed that the adjunctive
treatment of chronic periodontitis (i.e. scaling and root
planning) with a daily dietary supplementation with
omega-3 fatty acids and low-dose aspirin, increase the
production a variety of pro-resolution lipid mediators,
leading to a reduction in probing depths and a signifi-
cant attachment gain, as assessed after 3- or 6-month
treatment.
The observation that ATB-346 is capable of decreasing
periodontal inflammation and also prevent the occur-
rence of deleterious effects on the gastric mucosa sec-
ondary to the naproxen moiety, can thus be explained,
at least in part, by the release of H2S, which can induce
a shift from a pro-inflammatory to a pro-resolution sta-
tus, both locally and systemically (i.e., in the stomach
and periodontium, respectively).
The mechanisms and pathways of H2S signaling are
not yet completely understood and its regulation is so
complex that new mechanisms are continuously discov-
ered before the former mechanisms are fully understood
[49]. For example, it has been shown that H2S can not
only activate ATP-sensitive K+ (KATP) channels (involved
in vascular relaxation [50] and myocardial protection
[51]), but also close T-type calcium channels (involved
in visceral pain-like nociception and somatic hyperalge-
sia [52]), inhibit NF-κB signaling pathway (downregulat-
ing the expression of cytokines, chemokines, adhesion
molecules and apoptosis [53]), inhibit cytochrome oxi-
dase [54] and scavenge reactive oxygen and nitrogen
species (thus inhibiting oxidative stress and regulating
NO vascular effects [44]).
Regarding the effects of the administration of inorganic
sulfide salts on periodontal tissues, a previous study from
Irie et al. [31] shows that the topical application of 3 μmol
Figure 3 Gingival IL-1β and IL-6 contents are increased in rats with ligature-induced periodontitis but counterregulated by treatment
with either naproxen or ATB-346. IL-1β, IL-6 and IL-10 contents measured in rat gingival samples obtained from the different treatment groups.
*P < 0.05 and ***P < 0.001 vs. Sham; #P < 0.05; ##P < 0.01 and ###P < 0.001 vs. Vehicle (n = 6 for each group).
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Figure 4 Seven-day treatment with naproxen, but not ATB-346, induces gastric mucosa damage and increased myeloperoxidase activity
(MPO). MPO activity content (panel A) and tissue damage score (panel B), determined in rat stomach samples obtained from the different treatment
group. Panel C: Representative pictures of stomachs obtained from each experimental group (pictures corresponding to the naproxen and ATB-346
groups are also shown at higher magnification); yellow arrows indicate the presence of erosions. ***P < 0.001 vs. all the remaining experimental groups
(n = 5 for each group).
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NaHS into the gingival sulcus of the rat first molar in-
duces a transient increase of osteoclast differentiation with
up-regulation of RANKL expression in osteoblasts, thus
allowing the authors to conclude that H2S may contribute
to alveolar bone resorption through RANKL expression.
However, it is worth noticing that in the referred study,
the employed NaHS dose was the result of applying 3 μL
of a 1 M NaHS solution, a concentration that more resem-
bles H2S toxicology than the concentrations at which H2S
occurs under physiological conditions.
On the other hand, more recent studies using inor-
ganic sulfide doses within the μmol/kg/day range (as
used in this work), or in vitro concentrations within the
μM range (that usually occur in biological fluids), show
results in line with ours, in terms of H2S inhibiting activ-
ity on bone resorption. For example, Toker et al. [33]
showed that the systemic administration of NaHS at
three different doses (14, 28 or 70 μmol/kg/day) had no
impact on the alveolar bone loss, but a significantly
lower number of osteoclasts was observed by the au-
thors at the highest NaHS dose. Moreover, Lee et al. [55]
showed that NaHS inhibited the differentiation of mouse
bone marrow cells into multinucleated TRAP-positive
osteoclasts in vitro, in addition to reducing the mRNA
expression of molecules involved in both nicotine- and
LPS-induced osteoclastogenesis (such as RANKL, OPG,
M-CSF, MMP-9, TRAP, and cathepsin K), thus suggest-
ing that H2S has a potential therapeutic value for treat-
ment of bone diseases, such as periodontitis.
Conclusions
Despite the well-known beneficial effects of NSAIDs
during inflammatory conditions, their use as adjuvants
in the treatment of clinical periodontitis is not applic-
able, as the need for prolonged therapy would expose
the patient to the risk of severe cardiovascular, renal and
gastric side effects. From the results shown in this study,
we provide the first evidence that the presence of the
H2S-releasing moiety in the ATB-346 compound struc-
ture not only inhibits bone loss and inflammation in
experimental periodontits but, more importantly, it also
prevents the occurrence of deleterious effects on the
gastric mucosa due to prostaglandin inhibition. We thus
believe that these findings could further encourage clin-
ical studies looking for the impact of H2S-releasing
NSAID compounds as potential adjuvants for classical
periodontal treatment.
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